(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
28 February 2008 (28.02.2008)

PCT

(10) International Publication Number
WO 2008/024242 A2

(51) International Patent Classification:
A61K 48/00 (2006.01)

(21) International Application Number:
PCT/US2007/018048

(22) International Filing Date: 16 August 2007 (16.08.2007)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/838,812 18 August 2006 (18.08.2006) US
60/927,377 4 May 2007 (04.05.2007) US

(71) Applicant *(for all designated States except US)*: **ARGOS THERAPEUTICS, INC.** [US/US]; 4233 Technology Drive, Durham, North Carolina 27704 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **NICOLETTE, Charles** [US/US]; 5 Allen Moore Court, Durham, North Carolina 27703 (US). **BRAND, Stephen** [US/US]; 95113 Vance Knls, Chapel Hill, North Carolina 27517 (US). **ZHONG, Zhen** [CA/CA]; 60 Nathaniel Court, London, Ontario N5X 4H2 (CA). **WANG, Hao** [CA/CA]; 480 Sandybrook Drive, London, Ontario N5X 4H2 (CA). **ARP, Jacqueline** [CA/CA]; 345 Grandview Avenue, London, Ontario N6K 2T1 (CA). **RAMCHARRAN, Siobhan** [CA/CA]; 3663 Woodruff Crescent, Mississauga, Ontario L4T 1T8 (CA). **BAROJA, Mirin Lorea** [CA/CA]; 285 McGarrell Drive, Unit 2, London, Ontario N6G 5H3 (CA).


(74) Agent: **ARGOS THERAPEUTICS, INC.**; 4233 Technology Drive, Durham, North Carolina 27704 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: USE OF CD83 IN COMBINATION THERAPIES



(57) Abstract: The present invention relates to improved methods of suppressing and/or preventing an undesired immune response comprising the use of CD83. In some embodiments, CD83 is coadministered to a subject with at least one other immunosuppressive compound. Methods are also provided for generating tolerogenic dendritic cells and regulatory T cells. These cells can be used in vitro to produce additional cells for therapeutic purposes or they can be used in vivo to suppress and/or prevent an undesired immune response. Methods of the invention can be used to prevent or reduce the severity of autoimmune diseases and can also be used to induce tolerance to at least one therapeutic composition, such as a therapeutic protein or transplanted tissue.

WO 2008/024242 A2

Declaration under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *without international search report and to be republished upon receipt of that report*

— *with sequence listing part of description published separately in electronic form and available upon request from the International Bureau*